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Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor immu-
notherapy. However, potentially lethal toxicity associated with systemic administration of IL-
12 precludes its clinical application. Here we redesign the molecule in such a way that its anti-
tumor efficacy is not compromised, but toxic effects are eliminated. Deletion of the N-
terminal signal peptide of IL-12 can effect such a change by preventing IL-12 secretion from
cells. We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-
secreting (ns) IL-12 to tumor cells and examine the therapeutic and toxic effects in Syrian
hamster models of pancreatic cancer (PaCa). Strikingly, intraperitoneal delivery of Ad-TD-
nsIL-12 significantly enhanced survival of animals with orthotopic PaCa and cured peritoneally
disseminated PaCa with no toxic side effects, in contrast to the treatment with Ad-TD
expressing unmodified IL-12. These findings offer renewed hope for development of IL-12-
based treatments for cancer.
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Tumor-induced immune suppression is recognized as animportant mechanism by which tumors evade immune-mediated detection and destruction1. A number of strate-
gies to overcome this suppression have been evaluated, but local
IL-12 expression consistently appears to be one of the most
effective methods to achieve this due to its central role in T- and
NK-cell-mediated inflammatory responses2–5. Unfortunately,
clinical application of IL-12-based therapies remains problematic
due to the potential for rapid development of lethal inflammatory
syndrome6–10. The development of strategies to overcome IL-12-
mediated toxicity is currently the subject of intense research and a
number of modifications to IL-12 have been explored. Most
recently, tumor-targeted oncolytic adenoviral (AdV) delivery of
membrane-anchored IL-12 variants was analyzed in the context
of efficacy against metastatic pancreatic cancer11, 12. However,
delivery of therapeutically effective doses of AdV resulted in
membrane saturation of IL-12, leading to release into the serum
and subsequent toxicity. More promising drug-inducible
IL-12 systems allow easier management of IL-12 levels over
long periods, resulting in a reasonable degree of clinical efficacy.
However, inefficient transduction of tumor cells with carrier
vectors and the lack of simultaneous induction of inflammation
currently limits the overall anti-tumor effect of this
approach11, 13.
Tumor-targeted oncolytic viruses (TOVs) are attractive ther-
apeutic candidates for cancer treatment due to their ability to
replicate in and directly lyse tumor cells, release tumor antigens
from destroyed cancer cells and importantly induce local
inflammation, which contributes significantly to reversal of local
immune suppression and development of anti-tumor immune
responses14, 15. Furthermore, TOVs can be used to efficiently
deliver therapeutic genes specifically to the tumor site at an
increasing level following viral replication in tumor cells. The
first-generation, tumor-targeted oncolytic adenovirus,
an E1B55k-deleted oncolytic adenovirus (H101) was the first OV
therapy to be licensed for cancer treatment. However, although
clinical safety profiles were encouraging, few objective responses
were seen16, 17. It has subsequently been recognized that deletions
in the E1B55K and E3 gene regions in the virus had a significant
impact on the ability of these viruses to replicate efficiently within
cells18. Based on our improved knowledge of AdV biology18–20,
we have constructed a new-generation replicating AdV with triple
gene deletions (E1A CR2, E1B19K, and E3gp19K), Ad-TD-LUC.
This was used to deliver a modified IL-12 (nsIL-12, with deletion
of the IL-12 signal peptide) to Syrian hamster models of pan-
creatic cancer (PaCa), which are particularly suitable for these
investigations as they are permissive for AdV replication21, 22 and
as shown here for the first time, permissive for human IL-12
functions.
Oncolytic viruses encoding IL-12 have demonstrated strong
anti-tumor effects in preclinical models of cancers23–25; however,
systemic accumulation of IL-12 after delivery by oncolytic viruses
remains potentially lethal to patients10, 26. Here we report that
systemic delivery of the modified nsIL-12 using our adenovirus
Ad-TD-nsIL-12 to peritoneally disseminated and orthotopic
pancreatic tumors is an extremely effective anti-tumor therapy.
Importantly, no toxic side effects are observed, even when viruses
are administered at high doses that are usually associated with
lethal IL-12-mediated toxicity in these models.
Results
Ad-TD replicates selectively in cancer cells. Following a better
understanding of the functions of different adenovirus genes, we
have constructed a novel tumor-targeted replicating AdV, Ad-
TD-LUC, in which the E1ACR2, E1B19Kand E3gp19K genes
were deleted and the luciferase (LUC) open reading frame
inserted into the E3gp19K region (Fig. 1a). To analyze viral
selectivity and replication in tumor cells, we assessed viral repli-
cation in a panel of normal and tumor cell lines (Fig. 1b–k). Ad-
TD-LUC replicated efficiently in all cancer cell lines examined
(Fig. 1d–k), yet was significantly attenuated in normal cell lines
(Fig. 1b, c) in comparison to the wild-type Ad5 virus, which
replicated to high titers in these cell lines. Furthermore, Ad-TD-
LUC also demonstrated a superior in vivo selectivity. Tumor
tissues, lung, and liver were examined after intraperitoneal
administration of the virus into Syrian hamster bearing Hap-T1
orthotopic pancreatic cancer. While the viral E1A gene produced
by Ad5 could be detected in both tumor and normal tissues at all
time-points examined, E1A detected after Ad-TD-LUC treatment
was confined to tumor tissue and absent from normal lung and
liver tissues (Fig. 1l).
Ad-TD-nsIL12 replicates in and is cytotoxic to cancer cells.
Oncolytic viruses encoding IL-12 have demonstrated strong anti-
tumor effects in preclinical models of cancers23–25; however, even
direct intratumoral (i.t.) administration of these agents can result
in systemic accumulation of IL-12, which has the potential to
trigger lethal inflammatory syndrome. To investigate the potential
of IL-12 modified to prevent secretion from infected cells, Ad-TD
viruses expressing wild-type IL-12 (Ad-TD-IL-12) or modified
IL-12 (Ad-TD-nsIL-12) were constructed (Fig. 1a). The potency
of IL-12-armed viruses, control virus and wild-type Ad5 was
assessed in a panel of human cancer cell lines (Fig. 2a) and a
panel of Syrian hamster tumor cell lines (Fig. 2b). The three
mutant viruses were significantly more potent than Ad5 in all cell
lines examined. As expected from previous data regarding the
ability of oncolytic adenoviruses to replicate efficiently in Syrian
hamster models22, we found that Ad5 and our mutant viruses
could replicate in Syrian hamster tumor cell lines effectively and
at an equivalent level over a time course (Fig. 2c–g).
Modifying IL-12 does not affect its biological activity. Having
confirmed that the three viruses developed in this study were able
to selectively replicate in and kill tumor cells, we next investigated
the intracellular accumulation and secretion of human IL-12 after
infection of Syrian hamster tumor cell lines with Ad-TD-IL-12
and Ad-TD-nsIL-12. As shown in Fig. 3, while high levels of IL-
12 were detected from supernatants of Ad-TD-IL-12-infected
cells, very low levels of IL-12 were detected from supernatants of
Ad-TD-nsIL-12-infected cells (Fig. 3a–f). IL-12 was, however,
detected in lysates of Ad-TD-nsIL-12-infected cells (Fig. 3g, h),
although at significantly lower levels when compared to the Ad-
TD-IL-12-infected cells. The lower levels of IL-12 detected from
Ad-TD-nsIL-12-infected lysates corresponded with a decrease in
IL-12 mRNA detected from infected Hap-T1 cells at both 72 and
96 hpi compared to IL-12 mRNA detected in Ad-TD-IL-12-
infected cells (Fig. 3h, i). No differences in mRNA levels were
detected at early time points, suggesting a possibility that intra-
cellular accumulation of IL-12 may act to downregulate its own
expression at the mRNA level once an intracellular threshold is
reached.
Given that human IL-12 is non-functional in murine systems,
next we investigated whether human IL-12 could function within
the Syrian hamster immune system. Here we show, for the first
time, that recombinant human IL-12 is able to induce TNF-α
(Fig. 3j) and IFN-γ (Fig. 3k) expression in hamster splenocytes
ex vivo and induce proliferation of Syrian hamster, but not
murine, peripheral blood mononuclear cells (PBMCs) (Fig. 3l),
confirming that human IL-12 is functionally active in Syrian
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hamster models and deletion of the signal peptide has no
detrimental impact on its activity.
Ad-TD-nsIL-12 is effective in a subcutaneous PaCa model. To
investigate the anti-tumor efficacy of the Ad-TD-LUC virus and
IL-12-armed Ad-TDs, subcutaneous HPD1NR pancreatic tumors
were established in hamsters. Animals were treated i.t. six times
with 1 × 109 PFU/injection of Ad-TD-IL-12, Ad-TD-nsIL-12, Ad-
TD-LUC or PBS. Multiple virus administration was used based
on previous clinical studies and our recent study that demon-
strates that repeated injection of oncolytic adenovirus can result
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immune system against both adenovirus and tumor-associated
antigens27.
In this model, confinement of IL-12 expression to the tumor
mass limited the associated toxicity resulting in 100% tumor
eradication and survival of both Ad-TD-IL-12 and Ad-TD-nsIL-
12-treated animals (Fig. 4a, b). Successful oncolytic virus
strategies aim not only to eradicate the primary tumor, but also
to induce long-term anti-tumor immunity. To evaluate the
development of anti-tumor immunity for protection against
disease recurrence elicited by Ad-TD-nsIL-12 treatment, those
animals that had cleared their primary tumor after treatment with
Ad-TD-nsIL-12 were re-challenged four weeks later with
HPD1NR or control renal cancer HaK cells. Ad-TD-nsIl-12-
treated animals demonstrated development of immunity to
HPD1NR tumor cells, as evidenced by rapid clearance of these,
but not HaK cells nor HPD1NR co-injected with hamster α-CD3
depletion antibody (Fig. 4c).
Ad-TD-nsIL-12 can safely cure disseminated PaCa. To evaluate
the anti-tumor activity of Ad-TD-nsIL-12 in advanced PaCa, a
peritoneally disseminated PaCa model that rapidly recapitulates
(4–6 days) late-stage human PaCa28 was established in Syrian
hamsters (Supplementary Fig. 1a). SHPC6 cells were injected i.p.
and 4 days later, PBS or virus at a dose of 1 × 109 PFU was
administered i.p. on days 0, 2, and 4. Ad-TD-nsIL-12 treatment
resulted in 100% survival which persisted until termination of the
experiment (Fig. 5a). No animal displayed signs of treatment-
related toxicity. Treatment with Ad-TD-IL-12 resulted in only a
10% survival rate, with deaths occurring earlier than those in the
PBS-treated group (Fig. 5a). A dose reduction of Ad-TD-IL-12
did not alleviate IL-12-mediated toxicity, resulting in early death
of a large proportion of the animals treated and no improvement
in overall efficacy compared to the PBS treatment (Fig. 5b). To
evaluate the improvement in safety associated with administra-
tion of Ad-TD-nsIL-12 compared to Ad-TD-IL-12, liver function
was examined after PBS, Ad-TD-IL-12 (5 × 108 PFU) or Ad-TD-
nsIL-12 (1 × 109) were administered i.p. into hamsters bearing
peritoneally disseminated SHPC6 PaCa. Liver toxicity was
assessed by measuring aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and alkaline phosphatase (ALP) levels in
the serum on days 1, 3, and 5 post-injection. Significant elevations
in all three enzymes were detected in the Ad-TD-IL-12-treated
group at each time point whereas liver enzymes measured in Ad-
TD-nsIL-12-treated animals, which received double the dose of
virus, remained equivalent to those detected in PBS-treated ani-
mals (Fig. 5c). As expected, serum levels of IL-12 were higher
after treatment with Ad-TD-IL-12 compared to Ad-TD-nsIL-12
levels, which remained constant throughout the time-points
analyzed (Fig. 5d).
A further experiment was carried out in which one i.p.
injection of high dose (3 × 109 PFU) Ad-TD-nsIL-12 was
administered. No treatment-related deaths were observed and
the treated animals were completely cured, surviving until
termination of the experiment (Fig. 5e). Once again, induction
of long-term, tumor-specific immunity was observed after re-
challenge of hamsters previously treated with Ad-TD-nsIL-12 in
this model (Fig. 5f).
Ad-TD-nsIL-12 shows efficacy in an orthotopic PaCa model.
Ad-TD-nsIL-12 was evaluated further using an orthotopic PaCa
model to mimic a clinically unresectable disease scenario. The
hamster HapT1 PaCa cell line was effective for establishing
sizeable, metastasizing orthotopic tumors by day 6 post-injection
(Supplementary Fig. 1b, c)29. HapT1-tumors established in the
tail of the pancreas were treated i.p with PBS, Ad-TD-IL-12 or
Ad-TD-nsIL-12 (1 × 109 PFU/injection) every other day for six
doses. In this model, treatment with Ad-TD-nsIL-12 significantly
improved survival compared with PBS and Ad-TD-IL-12-treated
animals, the latter group experiencing rapid mortality due to IL-
12-mediated toxicity (Fig. 6a).
This model was used to assess an increased dose of Ad-TD-
nsIL-12 (2.5 × 109 PFU/injection, six times) vs. a reduced dose of
Ad-TD-IL-12 (5 × 108 PFU/injection, six times). Treatment with
a higher dose of Ad-TD-nsIL-12 dramatically increased the
survival rate compared to PBS, Ad-TD-LUC and Ad-TD-IL-12-
treated animals. Reduction of the Ad-TD-IL-12 dose adminis-
tered alleviated toxic effects, but efficacy remained significantly
lower than that following treatment with Ad-TD-nsIL-12
(Fig. 6b). At these doses (Ad-TD-IL-12 at 5 × 108 PFU/injection
and Ad-TD-nsIL-12 at 2.5 × 109 PFU/injection delivered six times
i.p) we saw evidence of tumor cell infection by all viruses by
immunohistochemical detection of viral proteins in the tumor
sections at day 7 following the last injection (Fig. 6c) and by the
titration of infectious virions recovered (Fig. 6d), which in all
cases were absent from tumor samples by day 14. Analysis of viral
E1A DNA produced by Ad-TD-nsIL-12 in tumor or normal
tissues using this model further supported the tumor specificity of
the nsIL-12-armed adenovirus at a dose of 2.5 × 109 PFU/
injection, with E1A being detected at much lower levels (close to
the limit of assay sensitivity) in normal lung or liver tissue
compared to tumor tissue (Fig. 6e). Analysis of the growth of
orthotopic Hap-T1 tumors following this regime demonstrated
that both Ad-TD-IL12 and Ad-TD-nsIL-12 caused dramatic
regression of the tumor size by 14 days compared to PBS and
control Ad-TD-LUC (Fig. 6f), and both viruses, at their respective
doses, enhanced CD3+ T-cell infiltration within tumor tissue
(Fig. 6g). As observed using the SHPC6 model of disseminated
PaCa, systemic IL-12 accumulation was detected for the duration
of viral infection only after treatment with Ad-TD-IL12 (Fig. 6h),
despite both viruses being detected at comparable levels in tumor
cells (Fig. 6c, d). Moreover, pathological examination of
hepatocytes after treatment with Ad-TD-LUC and Ad-TD-nsIL-
Fig. 1 A novel oncolytic adenovirus Ad-TD-LUC is tumor-selective in vitro and in vivo. a The basic structures of the Ad5 genome and derived mutants are
shown. The arrows indicate the deleted regions in the genome of adenovirus. IL-12 comprises p40 subunit and p35 subunit linked by an elastic peptide
(VPGVGVPGVG), with a signal peptide linked to the p40 subunit. Non-secreting (ns) IL-12 lacks this signal peptide. b−k Tumor selectivity was confirmed
by assessing replication of Ad-TD-LUC and wild type AdV in normal cells and in a panel of human cancer cells. Cell lines examined were normal human
bronchial epithelial cells (NHBE); primary culture hamster hepatocytes; pancreatic cancer cell lines (PaTu8988T; SUIT2; MiaPaCa2); lung cancer (A549);
prostate cancer (PC3); colorectal cancer (HCT116); ovarian cancer (SKOV3) and breast cancer (MCF-7). NHBE Cells were infected at an MOI of 100
particles/cell, the rest were infected at an MOI of 5 PFU/cell. Replication assays were carried out over a period of 72 h. Infectious virus production was
assessed by titration on JH293 cells and the titer as PFU/cell calculated and shown as mean and standard error of the mean (SEM). Statistical analysis was
performed using a two-way ANOVA test with Bonferroni post-test; *p< 0.05, **p< 0.01; ***p< 0.001. Experiments were performed in triplicate. l
Orthotopic PaCa tumors were established in Syrian hamsters using 3 × 106 Hap-T1 cells. Six days later Ad5 or Ad-TD-LUC were injected i.p. (n= 9/group)
on day 0, 2, 4, 6, 8, and 10 at a dose of 2.5 × 109 PFU/injection. Animals were killed on day 3, 7, and 14 after the last viral treatments. Tumors, lung, and
livers were analyzed by qPCR for copy numbers of the viral E1A gene. The sensitivity of the assay is illustrated by the dotted line. Mean and SEM are shown
for each group and compared using an independent t-test. ***p< 0.001
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12 demonstrated only mild blood vessel congestion and
eosinophilic degeneration, while Ad-TD-IL12 induced severe
blood vessel congestion, eosinophilic degeneration, apoptosis and
necrosis of hepatocytes (Fig. 6i), despite the dose of Ad-TD-IL-12
administered being five times lower than those of Ad-TD-nsIL-12
or Ad-TD-LUC. A dose escalation study of Ad-TD-nsIL-12
suggested that 2.5 × 109 was the optimal dose for delivery as
animals receiving higher doses of Ad-TD-nsIL-12 did not show
statistically improved responses to treatment demonstrating no
advantage of administration of increased doses of virus
(Supplementary Fig. 2a). At the highest dose examined, 2 × 1010
PFU/injection, the survival advantage conferred by Ad-TD-nsIL-
12 was actually abrogated, although serum levels of IL-12 at this
dose remained low (Supplementary Fig. 2b). However, both Ad-
TD-LUC and Ad-TD-nsIL-12 treatments at a such high does
resulted in severe hepatotoxicity, showing severe blood vessel
congestion as well as eosinophilic degeneration, apoptosis and
necrosis of hepatocytes (Supplementary Fig. 2c), suggesting that
the reduced survival of animals receiving the highest dose of Ad-
TD-nsIL-12 (2 × 1010 PFU/injection) may be derived from viral
toxicity and not IL-12 related toxicity.
Ad-TD-nsIL-12 efficacy is CD8+ T-cell dependent. Antibodies
against Syrian hamster immune cells are limited, thus to inves-
tigate further the contribution of immune subsets to treatment
efficacy, we developed an α-hamster CD3+ depletion antibody30.
Functional hamster α-CD8+ antibodies do not currently exist,
thus in this instance, CD3+ CD4− cells are taken to be, in the
majority, CD8+ populations. Depletion of CD3+, but not CD4+
subsets in HPD1NR subcutaneous tumor-bearing hamsters had a
significant detrimental impact on treatment efficacy suggesting
that Ad-TD-nsIL-12 acts via a CD3+ CD4− (CD8+) mechanism
to eliminate tumors (Fig. 7a, b). Despite this, analysis of CD3+
and CD4+ infiltration into subcutaneously implanted tumors
using IHC shows a significant increase in both these populations
after treatment with both Ad-TD-IL-12 and Ad-TD-nsIL-12
(Fig. 7c–f). CD3+/CD4+ populations were examined further in
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Fig. 2 Ad-TD-LUC and IL-12-armed viruses replicate in and are cytotoxic cancer cell lines. a, b To assess virus cytotoxicity, cell proliferation assays
(Promega) were carried out in all human a and Syrian hamster b tumor cell lines. Cells were infected with Ad5, Ad-TD-LUC or Ad-TD-IL-12 or Ad-TD-nsIL-
12 and incubated for 6 days at 37 oC. The amount of virus particles required to kill 50% of the cells is shown as EC50 (PFU/cell) and shown as mean and
SEM compared using an independent t-test. c−g Replication assays were carried out in hamster pancreatic cancer cell lines, HPD1NR, Hap-T1, SHPC6 and
IPAN, and hamster kidney cancer cells (HaK) at an MOI of 5 PFU/cell. Mean and SEM are shown for each group and compared using an independent t-
test. *p< 0.05, **p< 0.01, ***p< 0.001
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subcutaneous tumors treated once i.t with PBS or virus (1 × 109
PFU) (Fig. 7g). At all time-points, treatment with Ad-TD-IL-12,
but not Ad-TD-nsIL-12 resulted in significant increases in CD3+
CD4− (CD8+) populations in the spleen. Ad-TD-nsIL-12 treat-
ment only resulted in a transient increase in CD3+ CD4+ and
CD3+ CD4− (CD8+) populations in local draining lymph nodes
but splenic numbers were unchanged compared to the control
virus, suggesting that anti-tumor efficacy of nsIL-12 treatment
depends more on alteration of T-cell function than alterations of
total numbers of circulating lymphocytes (Fig. 7g).
Ad-TD-nsIL-12 reduces expression of inflammatory cytokines.
To examine inflammatory responses further, hamster-specific
qPCR primers were developed in our laboratory for analysis of
inflammatory mediators (Table 1). IL-12 effects are mediated
largely through IFN-γ and indeed, tumor IFN-γ levels were ele-
vated by both Ad-TD-IL-12 and Ad-TD-nsIL-12 compared to
treatment with Ad-TD-LUC or PBS. However, Ad-TD-IL-12
elevated local levels earlier and to a significantly higher degree
than Ad-TD-nsIL-12 (Fig. 8). This pattern was mirrored in the
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Fig. 3 Ad-TD-nsIL-12 produced IL-12 is functionally active in Syrian hamster cells. a−h To detect IL-12 expression from Ad-TD-IL-12/nsIL-12 in vitro, tumor
cells were infected with Ad-TD- IL-12/nsIL-12 or Ad-TD-LUC at an MOI of 5 PFU/cell. Human cancer cells a or Syrian hamster tumor cell supernatants b−f
or disrupted cell lysates g were collected every 24 h for 96 h and assayed for IL-12 by ELISA h Intracellular levels of IL-12 were detected in HapT1 cells
infected with Ad-TD-IL-12 or Ad-TD-nsIL-12 at an MOI of 5 PFU/cell i mRNA levels of IL-12 were detected in HapT1 cells infected with Ad-TD-IL-12 or Ad-
TD-nsIL-12 at an MOI of 5 PFU/cell. mRNA levels relative to β-actin are shown. j, k Recombinant human IL-12 protein (rhIL-12) induced TNF-α j and IFN-γ k
expression in hamster splenocytes. mRNA levels relative to β-actin are shown. l Human, hamster, and mouse PBMCs were incubated in the presence of
(rhIL-12) or lysate from Hap-T1 cells infected with Ad-TD-IL-12 or Ad-TD-nsIL-12, each at 2 ng/ml, or Ad-TD-LUC infected lysate as a control. Cell
proliferation was measured using MTS assay 48 h post-treatment. All experiments were performed in triplicate and the mean and standard error of the
mean are shown for each group and compared using an independent t-test. *p< 0.05, **p< 0.01, ***p< 0.001
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01385-8
6 NATURE COMMUNICATIONS | 8:  1395 |DOI: 10.1038/s41467-017-01385-8 |www.nature.com/naturecommunications
21, IFN-β, IL-12, and IP-10, an IFN-γ-induced chemokine31.
Thus, IL-12 release from tumor cells lysed by Ad-TD-nsIL-12 was
able to stimulate effective, but reduced inflammatory responses
compared to the more sustained release of IL-12 from tumor cells
infected with Ad-TD-IL-12. Splenic IFN-γ and IP-10 and lymph
node IFN-γ were also produced at lower levels after treatment
with Ad-TD-nsIL-12 compared to Ad-TD-IL-12 and resolution
occurred more rapidly following nsIL-12 treatment. These
observations may account for the reduction in toxicity associated
with delivery of the modified nsIL-12 by Ad-TD, compared to
delivery of wild-type IL-12. Tumor CD83 expression suggested
that both viruses were able to recruit mature dendritic cells with
equal efficiency. Interestingly, IL-6 levels generated in response to
nsIL-12 were not elevated compared to PBS or Ad-TD-LUC
treatment, whereas Ad-TD-IL-12 treatment resulted in sig-
nificantly enhanced levels. Elevated IL-6 levels in patients with
pancreatic cancer correlate with poor survival32, possibly due to
E-cadherin down-regulation increasing metastasis33. Tumor IL-
10 levels were also elevated more significantly after treatment
with Ad-TD-IL-12 compared to Ad-TD-nsIL-12 or Ad-TD-LUC.
Discussion
Tumor-targeted oncolytic viruses specifically infect and lyse
tumor cells, release tumor-associated antigens (TAAs) and induce
anti-tumor immune responses. Adenoviruses have efficacy, safety,
and manufacturing characteristics that make them attractive as
oncolytic virus candidates and suitable gene-delivery vectors34.
Promising clinical data of oncolytic adenovirus dl1520 have
shown both its anti-tumor potential and safety35. However,
mutant adenoviruses with E1B-55K gene deletions are markedly
attenuated as oncolytic agents as E1B-55K is required for mod-
ulation of viral and cellular mRNA nuclear transport, stimulating
late viral mRNA translation36. Subsequent generations of onco-
lytic adenoviruses contain rational gene deletions based on an
improved understanding of the viral gene functions, however, the
majority of oncolytic adenoviruses used clinically still have low
potency due to E3B region deletions that result in rapid viral
clearance and/or decreased viral activity18, 37. In this study, we
created a new generation of oncolytic adenoviruses, “Ad-TD”,
with three deleted adenovirus genes. This virus is selective for
tumor cells through the deletion of E1A conserved region 2 (CR2)
and E1B-19K38. The third deletion, E3gp-19K has previously
been shown to result in an increase in the anti-tumor effects of
the virus18. We found that deletion of these genes improved
adenovirus tumor selectivity in vitro and in vivo (Figs 1, 2) and
these viruses displayed improved anti-tumor efficacy compared to
first generation of oncolytic adenovirus dl152039. In addition,
therapeutic gene expression is driven by the endogenous pro-
moter of E3-gp19k, which ensures stable and high-level gene
expression during viral replication in tumor cells. Of note, the
Ad-TD adenovirus retains the E3B genes.
The potent anti-tumor properties of IL-12 were first observed
more than 20 years ago40. The multiple anti-tumor mechanisms
associated with IL-12 have been intensively investigated, but
clinical application remains elusive due to its short half-life and
systemic toxicity41. Local and consistent delivery of IL-12 into the
tumor microenvironment to achieve durable, low-level IL-12
expression may resolve these issues. To improve the safety and
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Fig. 4 Ad-TD-nsIL-12 is an effective treatment for subcutaneous hamster PaCa. 2 × 106 HPD1NR cells were seeded into the right flank of Syrian hamsters.
When tumor volumes reached 300mm3, seven hamsters per group were each injected i.t. with 100 µl PBS, 1 × 109 PFU Ad-TD-LUC or Ad-TD-nsIL-12/IL-12
on days 0, 2, 4, 6, 8, and 10. a Mean tumor sizes and SEM are shown for each group and compared using a one-way ANOVA with post hoc Tukey’s
Multiple Comparison Test. *p< 0.05, ***p< 0.001. b Kaplan–Meier survival curves were generated and a log-rank (Mantel–Cox) test used to analyze
significance. **p< 0.01, ***p< 0.001. Treatment with both Ad-TD-IL-12 and Ad-TD-nsIL-12 resulted in 100% survival in this model. c Hamsters that had
cleared tumors after i.t treatment with Ad-TD-nsIL-12 during efficacy experiments were re-challenged 4 weeks later in the opposite flank with 4 × 106
HPD1NR or 5 × 106 HaK cells, or were injected i.p with anti-CD3 mAb (500 μg/injection) on the day before re-challenge with HPD1NR cells. In parallel,
naive hamsters were injected with 5 × 106 HaK cells at the same sites and tumor growth measured and analyzed using a one-way ANOVA with post hoc
Tukey’s Multiple Comparison Test. ***p< 0.001
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Fig. 5 Ad-TD-nsIL-12 is a safe and effective treatment for peritoneally disseminated PaCa. 1 × 107 SHPC6 cells were seeded into the peritoneal cavity of
Syrian hamsters. Four days later, 10 hamsters per group were each injected i.p with PBS or viruses. a PBS or 1 × 109 PFU each virus was injected i.p on days
0, 2, and 4 and survival monitored. b PBS or varying doses of Ad-TD-IL-12 (2.5 × 108 to 1 × 109) were injected i.p. on days 1, 2, and 4 and survival monitored.
c, d Using the same tumor model, nine hamsters per group were each injected i.p with 500 µl PBS, 1 × 109 PFU Ad-TD-LUC, 5 × 108 PFU Ad-TD-IL-12 or 1 ×
109 PFU Ad-TD-nsIL-12 on day 0. Serum was collected on days 1, 3, and 5 for detection of the levels of ALT, AST, and ASP, respectively, c or IL-12 d
detected by ELISA. Mean and SEM are shown. Statistical analysis was carried out using a one-way ANOVA with post hoc Tukey’s Multiple Comparison
Test or independent t-test. *p< 0.05, **p< 0.01, ***p< 0.001. e 3 × 109 PFU Ad-TD-nsIL-12 or PBS was administered i.p on day 0 and survival monitored
(n= 10). f PBS or 1 × 109 PFU Ad-TD-nsIL-12 was injected i.p on days 0, 2 and 4 (n= 10). Forty days later, surviving hamsters previously treated with Ad-
TD-nsIL-12 were re-challenged with 1 × 107 SHPC6 cells. Age-matched naive hamsters also were peritoneally injected with SHPC6 cells as control. Survival
was monitored. In each case, Kaplan–Meier survival curves were generated and significance assessed using the log-rank (Mantel–Cox) test.
**p< 0.01, ***p< 0.001
Fig. 6 Ad-TD-nsIL-12 is an effective and safe treatment for orthotopic PaCa in Syrian hamsters. Six days after Hap-T1 cells were seeded into the tail of the
pancreas, hamsters were injected i.p. with 500 µl PBS, 1 × 109 PFU Ad-TD-LUC, Ad-TD-IL-12 or Ad-TDnsIL-12 (a) or 2.5 × 109 PFU Ad-TD-LUC, 2.5 × 109
PFU Ad-TD-nsIL-12 or 5 × 108 PFU Ad-TD-IL-12 (b) (n= 7/group) on days 0, 2, 4, 6, 8, and 10. Kaplan–Meier survival curves were generated. Significance
was assessed using the log-rank (Mantel–Cox) test. *p< 0.05, **p< 0.01. c−h Animals were treated as b (n= 3/time point/group) and killed on day 3, 7,
and 14 after last viral treatments. c Representative images of immunohistochemical staining for Hexon at day 7. Hexon-positive cells were counted in five
high-power fields (HPF) from each tumor section (×200). ND: not detected. d Infectious virion recovery from tumor tissue was determined by TICD50
using JH293 cells. e Tumors, lung, and livers were analyzed by qPCR for the copy numbers of the viral E1A gene after treatment with Ad-TD-nsIL-12 at
2.5 × 109 PFU/injection on day 0, 2, and 4. The sensitivity of the assay is illustrated by the dotted line. Mean and SEM are shown for each group and
compared using an independent t-test. *p< 0.05, **p< 0.01. fMean tumor volumes and SEM are shown for each group. Statistical analysis was carried out
using a one-way ANOVA with post hoc Tukey’s Multiple Comparison Test. *p< 0.05. g Representative images of immunohistochemical staining for CD3
at day 7. Quantitative scores of lymphocyte infiltration within tumors are shown (right panel) from five HPF from each tumor section (×200). The scoring
was conducted within the tumor and stroma and necrotic areas were avoided. The extent of positive cells was categorized into the following four grades: 1,
<15 cells/HPF; 2, 16–30 cells/HPF; 3, 31–45 cells/HPF; 4, >45 cells/HPF. ND: not detected. h IL-12 expression in sera was detected by ELISA. i
Representative histopathology of HE staining of livers after three i.p injections of virus into hamsters bearing orthotopic PaCa tumors (n= 3/group) on day
0, 2, and 4, using the same dose as in b. Livers were collected one day following the last injection and analyzed using HE staining (×200)
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the signal peptide required for secretion from cells and used our
adenovirus AD-TD to deliver this directly or systemically to a
number of different tumor models. When Ad-TD-nsIL-12 was
injected i.p into hamsters bearing intraperitoneally disseminated
SHPC6 PaCa, only low levels of IL-12 were detected in peripheral
blood on day 1, 3, 5, and no obvious changes of ALT, AST and
ALP liver enzymes were detected (Fig. 5). Delivery of unmodified
IL-12 resulted in high levels of peripheral IL-12 and elevations in
liver enzyme levels, consistent with severe liver blood vessel
congestion, eosinophilic degeneration and hepatocyte apoptosis
and necrosis (Fig. 6), indicative of induction of systemic toxicity.
By preventing IL-12 secretion from tumor cells, nsIL-12, tumor-
associated antigens and new Ad-TD-nsIL-12 virions are released
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the dissemination of IL-12 to the local tumor environment where
effective anti-tumor immunity was elicited (Fig. 6).
It has been reported that human IL-12 does not stimulate
mouse PBMC proliferation42, but no study has been published
assessing the effect of human IL-12 on hamster PBMCs. PBMC
proliferation assays presented here demonstrate that human IL-
12 stimulates both human and hamster PBMCs proliferation, but
not mouse PBMCs. In addition, rhIL-12 was able to effectively
stimulate IFNγ and TNFα expression by activated splenocytes
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effective model for assessing the anti-tumor effects of both
oncolytic adenoviruses and human inflammatory cytokines.
Given previous reports of the ability of IL-12 to promote T-cell
proliferation and program effector functions within the stable
population of human CD8+ effector memory T cells in vivo43, 44,
we examined the reliance of our treatment on these immune
subsets. Ad-TD-nsIL-12 therapy generated robust anti-tumor
memory T cells as evidenced by rejection of secondary tumors.
The lack of suitable research tools for analysis of Syrian hamster
immune subsets has limited the scope of research possible in this
model, but we have developed and validated a number of Syrian
hamster-specific antibodies and qPCR primers that allow initial
investigation of the immune responses elicited by our viruses.
Depletion of CD4+ T cells had no effect on treatment efficacy,
whereas depletion of CD3+ cell populations had a negative
impact on treatment efficacy in vivo (Fig. 7). Taken together these
results suggest an importance of CD3+ C4− (CD8+) cells for
treatment efficacy.
Further investigation of immune functions, using FACS ana-
lysis and qPCR detection methods developed in our laboratory
revealed that Ad-TD-nsIL-12 therapy had no effect on splenic
T cells and only transiently increased the percentages of CD4+
and CD8+ (CD3+ CD4−) populations in local draining lymph
nodes compared with the control virus, suggesting that anti-
tumor efficacy of nsIL-12 treatment depends more on modifica-
tion of T-cell function than alterations of total numbers of cir-
culating lymphocytes (Fig. 7), although currently the lack of tools
available for analysis of T-cell activation status in Syrian hamster
models precludes confirmation of this.
IL-12 effects are mediated largely through IFN-γ and indeed,
tumor IFN-γ levels were elevated by both Ad-TD-IL-12 and Ad-
TD-nsIL-12 compared to treatment with Ad-TD-LUC or PBS
(Fig. 8). However, Ad-TD-nsIL-12 elevated local levels of IFN- γ
and other inflammatory cytokines later and to a lesser extent than
Ad-TD-IL-12. Splenic IFN-γ and IP-10 and lymph node IFN-γ
were also produced at lower levels after treatment with Ad-TD-
nsIL-12 compared to Ad-TD-IL-12. These observations suggest
that the improved safety associated with nsIL-12 delivery may be
due to dampening, but not abrogation of the inflammatory
responses generated by IL-12 and this hypothesis warrants further
investigation. Tumor IL-10 levels were also elevated more sig-
nificantly after treatment with Ad-TD-IL12 compared to Ad-TD-
nsIL12 or Ad-TD-LUC. A wealth of evidence now exists to
suggest that IL-10 functions as both an immune-suppressive and
immune-stimulating or anti-tumor cytokine, depending on the
context of its expression45–47, thus the role of IL-12-induced IL-
10 in this setting requires further study.
In this study, we have developed a robust and safe IL-12 based
immune-viro-therapeutic agent that can be delivered locally or
systemically to tumors. Syrian hamster models of pancreatic
cancer, which can accurately reflect stages of tumorigenesis in
humans, were treated effectively and safely using Ad-TD-nsIL-12
using treatment regimes comparable to those currently applied
clinically (Figs. 4−6). However, further assessment of the phar-
macology and toxicology of this approach is still warranted prior
to translation of this therapy into early stage clinical trials for
pancreatic cancer. Of note, this agent might be also effective for
other advanced solid tumors such as gastric, colorectal, and
ovarian cancers for which the virus can be intraperitoneally
injected. In summary, the approach developed in this study offers
renewed hope for development of IL-12-based treatments for
cancer.
Methods
Study design. The objective of this study was to investigate the functional efficacy
and safety of modified IL-12 when delivered to in vivo tumor models using a new
oncolytic adenovirus. All hamster procedures were approved by the Animal
Welfare and Research Ethics Committee of Zhengzhou University (Zhengzhou,
China). For in vivo experiments, power calculations were carried out to determine
required sample sizes using G*Power 348, F-test ANOVA repeated measures setting
parameters of α= 0.1, power= 90%, effect size= 0.5, group= 3. In subcutaneous
tumor models, animals were randomly assigned by an independent animal care-
taker to treatment groups by matching tumor sizes prior to treatment. Tumor
growth was measured using electronic callipers until a tumor measured 2.0 cm in
diameter or ulcerated, at which point the animal was killed. Tumor growth curves
were terminated upon the death of the first animal in each group, but group
survival was monitored until the experimental endpoint (all animals in group
deceased, or 60 days post treatment). For orthotopic and disseminated pancreatic
cancer models, animals were assigned randomly to treatment groups and animal
survival was monitored by assessment of animal well-being every other day.
Experimental endpoints in these models were 200 days post treatment. Animal
caretakers were blinded to treatment groups in all cases.
Cell lines. The Syrian hamster pancreatic ductal adenocarcinoma (PDAC) cell lines
HPD1NR (maintained in Roswell Park Memorial Institute (RPMI) 1640 with 10%
FCS), Hap-T1, SHPC6, IPAN and the renal tumor cell line HaK were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FCS. SHPC6 and IPAN
were kindly provided by W. Wold (St. Louis University, St. Louis, MO, USA).
HPD1NR and Hap-T1 cell lines were purchased from the German Collection of
Microorganisms and Cell Cultures. The HaK cell line was purchased from the
American Type Culture Collection (ATCC). JH293, the human kidney epithelial
cell line transformed with Ad5 DNA, was obtained from the Cancer Research UK
Central Cell Services (London, United Kingdom) and maintained in DMEM with
10% FCS. Normal human bronchial epithelial cells (NHBE) were obtained from
Cambrex (Cambridge, UK) and maintained in Bronchial Epithelial Growth Med-
ium (BEGM) (Cambrex). Primary culture hamster hepatocytes (maintained in
DMEM with 10% FCS) were isolated and cultured in our lab. All cells were
maintained at 37 °C in a humidified atmosphere containing 5% CO2 and confirmed
to be mycoplasma-free before being used experimentally.
Viruses and antibodies. Adenovirus type 5 (Ad5) mutants were generated by
homologous recombination as described previously49. The complete Ad5 genome
was used as the backbone in all new mutants and was derived from the pTG3602
plasmid. The following viruses were generated: Ad-TD (triple deletion: E1ACR2,
E1B19K, and E3gp19K-deleted), Ad-TD-LUC (luciferase, from pGL3-Basic Vector
Fig. 7 Ad-TD-nsIL-12 efficacy is dependent on hamster CD3+/CD4− immune cell subsets. a, b Syrian hamsters were inoculated subcutaneously with 2 ×
106 HPD1NR cells. The established tumors were injected i.t. with 1 × 109 PFU Ad-TD-nsIL-12 or PBS (n= 7/group) on day 0, 2, 4, 6, 8, and 10. Control IgG
and either mouse anti-hamster CD3 mAb (4F11) a or CD4 mAb b were injected i.p. at doses of 500 μg/injection every fourth day from the day before the
viral therapy to the end of the experiment and FACS analysis used to confirm the depletion. Mean tumor volumes and SEM are shown for each group.
Statistical analysis was carried out using a one-way ANOVA with post hoc Tukey’s Multiple Comparison Test. *p< 0.05, ***p< 0.001. c–g 2 × 106 HPD1NR
cells were seeded into the right flank of Syrian hamsters. When tumor volumes reached 300mm3, nine hamsters per group were each injected i.t with PBS,
1 × 109 PFU Ad-TD-LUC or Ad-TD- IL-12/nsIL-12 on day 0. On days 3, 7, and 21 tumors were collected and processed for IHC. c Representative images of
immunohistochemical staining for CD3 and CD4 at day 7 (×200). d−f Quantitative scores of lymphocyte infiltration within tumors. Lymphocytes were
counted in 5 HPFs randomly selected from each tumor section (×200). The scoring was conducted within the tumor and stroma; necrotic areas were
avoided. The extent of lymphocyte infiltration was categorized into the following four grades: 1, <25 cells/HPF; 2, 25–49 cells/HPF; 3, 50–75 cells/HPF; 4,
>75 cells/HPF. Statistical analysis was carried out using a one-way ANOVA with post hoc Tukey’s Multiple Comparison Test. *p< 0.05, **p< 0.01,
***p< 0.001. g Spleens and lymph nodes were collected and analyzed by FACS for CD3 and CD4 expression at the time points shown. Mean expression
and SEM is plotted (n= 3/group). Statistical analysis was carried out using a one-way ANOVA with post hoc Tukey’s Multiple Comparison Test. *p< 0.05,
**p< 0.01, ***p< 0.001
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(Promega), Ad-TD-IL-12 (p40 with signal peptide and p35 without signal peptide
fragments were cloned from the cDNA derived from RPMI-8866 cells, linked with
elastin cDNA by PCR) and nsIL-12 (non-secreted IL-12, p40, and p35 without
signal peptide fragments were cloned from the former IL-12 by PCR). LUC, IL-12,
and nsIL-12 genes were driven by the endogenous E3gp19k promoter50. The
mouse monoclonal antibody (mAb) against Syrian hamster CD3e (clone 4F11,
IgG1 isotype), mAb against mouse CD4 (GK1.5, cross-reacting with Syrian ham-
ster) and anti-KLH mAb were prepared as previously described30, 50.
Cytotoxicity assay. Cells were seeded at 2 × 103 to 4 × 103 cells per well in 96-well
plates and infected with viruses 16–18 h later at starting MOI = 1000 PFU/cell. Cell
survival on day 6 after viral infection was determined by MTS assay as detailed by
the manufacturer (Promega) and EC50 values (viral dose killing 50% of tumor
cells) were calculated as previously described18. All assays were performed at least
three times.
Viral replication assay. Cells were seeded at 2 × 105 cells per well, in three wells of
6-well plates in medium with 10% FCS, and infected at 100 particles or 5 plaque-
forming units (PFU)/cell of Ad5 or Ad-TD-LUC/IL-12/nsIL-12 16−18 h later.
Primary culture hamster hepatocytes were infected immediately after isolation.
Samples were collected in triplicate at 24-hour intervals up to 72 or 96 h after
infection, freeze-thawed three times, and titrated on JH293 cells to determine the
50% tissue culture infective dose (TCID50) as previously described18.
TNF-α and IFN-γ expression induced by IL-12. Hamster splenocytes were
obtained from healthy donors. A total of 4 × 107 fresh splenocytes were seeded in a
12-well plate at a concentration of 2 × 106 cells/ml and stimulated with PHA for
3 days. The activated splenocytes were seeded in a 12-well plate at a density of 4 ×
106 cells/well and incubated with 100 U/ml of human IL-2 for 24 h. The activated
splenocytes were washed with PBS, then seeded in a 12-well plate at a density of
4 × 106 cells/well and incubated with human rIL-12 for 24 or 48 h at 37 °C. The
mRNA levels of TNF-α and IFN-γ were detected by qPCR.
PBMC proliferation assay. Human, hamster, and mouse peripheral blood was
obtained from healthy donors. PBMCs were separated on a Ficoll-Hypaque density
gradient. A total of 8 × 106 fresh PBMCs were seeded in a 6-well plate at a con-
centration of 2 × 106 cells/ml and stimulated with PHA for 3 days. The activated
PBMCs were seeded in a 96-well plate at a density of 1 × 105 cells/well in a final
volume of 50 µl and incubated with 50 µl of the lysate of Hap-T1 cells infected with
Ad-TD-IL-12 or Ad-TD-nsIL-12 for 48 h at 37 °C. PBMC proliferation was
determined by MTS assay. rIL-12 (2 ng/ml) was used as a positive control. Samples
were set-up in triplicate.
ELISA. Cell lysate, supernatant and serum samples were generated and processed
as described in other sections of the methods. IL-12 levels were quantified using an
IL-12-specific ELISA (eBioscience) according to the manufacturer’s instructions
and 1:10–200 dilutions were used, with samples tested in triplicate.
Real-time PCR. Fresh tissues were homogenized and total RNA extracted using
Trizol (Invitrogen). cDNA was synthesized by reverse transcription (Promega).
qPCR was carried out using the Bio-Rad CFX Real-Time PCR System and the
SYBR Green assay (Bio-Rad) to quantify cytokine expression. Primers of Syrian
hamster TNF-α, IFN-γ, IP10, CD83, IL-1β, IL-2, IL-6, IL-10, IL-12, IL-21, and β-
actin genes (Table 1) were designed using Primer Premier 5.0 software (Premier)
and constructed by Sigma-Aldrich. Data were analyzed using Bio-Rad CFX
Manager (Bio-Rad). Tissue DNA was extracted using the DNeasy blood and tissue
kit (Qiagen). qPCR was carried out using the ABI STEPONE PLUS system and the
SYBR Green assay (TAKARA) to detect viral genome in tissues. The primers of
adenovirus E1A gene are E1A-Forward: 5′-TGATCGATCCACCCAGTGAC-3′
and E1A-Reverse: 5′-ATGACAAGACCTGCAACCGT-3′. Data were analyzed
using ABI STEPONE PLUS system software. Results were normalized to PBS-
treated group values.
Histopathological examination and immunohistochemistry. The tissues col-
lected at different time points were processed and stained by H&E staining or
immunohistochemistry (IHC) for CD3 and CD4 as previously described18.
FACS analysis. Spleens and draining lymph nodes were extracted from hamsters,
combined with complete T-cell medium (RPMI medium, 10% FCS, 1% penicillin/
streptomycin, 1% sodium pyruvate) then pushed through a 70 µm cell strainer to
create a single cell suspension. Cells were centrifuged and the pellet incubated in 5
ml red blood cell lysis buffer (Sigma-Aldrich). Splenocytes and lymph node cells
(1 × 106) were prepared and stained with mAb against Syrian hamster CD3 and
mAb against mouse CD4-conjugated with FITC (GK1.5, cross-reactive with Syrian
hamster, BD), followed by secondary APC-conjugated rabbit anti-mouse antibody
for CD3 staining (BD). Cells were acquired on a FACS scanner, and data were
analyzed using FlowJo software (Tree Star Inc).
Assessment of infectious virus. Fresh tumor tissues were homogenized and
titrated on JH293 cells to determine the 50% tissue culture infective dose (TCID50)
as previously described18. Viral DNA levels were evaluated in tumors and livers
using real-time PCR as described above and previously30.
In vivo animal studies. Subcutaneous tumor model: A total of 2 × 106 HPD-1NR
cells were implanted subcutaneously into the right flank of female, 4-week to 5-
week-old Syrian hamsters. When tumors reached 6−8 mm in diameter, hamsters
were stratified into groups of seven animals to receive 50 or 100 µl intratumoral (i.t)
injections of Ad-TD-LUC, Ad-TD-IL-12, Ad-TD-nsIL-12, or PBS as specified in
the figure legends. The injections were introduced through a single central tumor
puncture site, and three to four needle tracks were made radially from the center
while virus was injected as the needle was withdrawn. Tumor volumes were esti-
mated (volume = (length × width2 × π)/6) twice weekly until tumors reached 2.0
cm in diameter or tumor ulceration occurred.
For biological time-point experiments to investigate functional mechanisms,
hamsters were stratified into groups when tumors reached 6−7 mm in diameter
and treated once on day 0. On day 3, 7, and 21, tumors, lymph nodes, and spleens
were collected from three animals in each group to investigate lymphocyte
populations, immunohistochemical staining for CD3 and CD4 expression in tumor
tissues and tumor-specific immunity.
Orthotopic pancreatic cancer model. 4-week to 5-week-old Syrian hamsters were
anaesthetized with 10% chloral hydrate by an intraperitoneal (i.p) injection.
Hamsters were placed in the dorsal decubitus position, and a left subcostal incision
was made. The pancreas was carefully exposed, and 50 µl of tumor cell suspension
(6 × 107 cells/ml) was injected into the tail of the pancreas with a 25-gauge needle.
A technically successful injection was characterized by the formation of a visible
bubble within the pancreatic parenchyma. The needle was slowly withdrawn to
avoid macroscopic cell spread from the injection site. The pancreas was then
returned to the peritoneal cavity, and the abdominal wall was closed in two layers
with nylon sutures. Six days later, the tumor volumes reached to 4–5 mm in
diameter, and seven hamsters per group were each injected i.p with 500 µl PBS, 1 ×
109 PFU Ad-TD-LUC or 5 × 108 PFU Ad-TD-IL-12 or 1 × 109 PFU Ad-TD-nsIL-
12 on days 0, 2, 4, 6, 8, and 10. The survival of hamsters was monitored.
Intraperitoneally disseminated pancreatic cancer model. A total of 1 × 107
SHPC6 cells were seeded into the lower right peritoneal cavity of Syrian hamsters.
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Four days later, 10 hamsters per group were injected i.p with 500 µl PBS, 1 × 109
PFU Ad-TD-LUC or 5 × 108 PFU Ad-TD-IL-12 or 1 × 109 PFU Ad-TD-nsIL-12 on
days 0, 2, 4. Alternative doses were given as indicated in the text or figure legend.
The survival of hamsters was monitored.
Hepatotoxicity evaluation. Three hamsters per group per time point were injected
i.p with 1 × 107 SHPC6 cells. Four days later, nine hamsters per group were each
injected i.p with 500 µl PBS, 1 × 109 PFU Ad-TD-LUC or 5 × 108 PFU Ad-TD-IL-
12 or 1 × 109 PFU Ad-TD-nsIL-12 on days 0. Blood was collected from hamsters
from the retro-orbital sinus, and the sera were analyzed for transaminase levels and
IL-12 expression on day 1, 3, 5.
Re-challenge of tumor free animals. The hamsters that underwent complete
subcutaneous tumor regression following Ad-TD-IL-12 or Ad-TD-nsIL-12 treat-
ment were re-challenged with 4 × 106 HPD-1NR cells (twice the number of cells
compared to the primary tumor cell inoculation) or 5 × 106 HaK cells after primary
tumors had not been detected for 1 month. One group of the cured animals were
injected i.p with anti-CD3 mAb on the day before the re-challenge with 4 × 106
HPD-1NR cells. Tumor volumes were measured twice weekly. SHCP6 cell re-
challenge is described in the figure legend.
CD3 and CD4 depletion in vivo. A total of 2 × 106 HPD-1NR cells were implanted
subcutaneously into 4-week to 5-week-old Syrian hamsters. When tumors reached
300 mm3, hamsters were distributed between the treatment and the control groups
by matched tumor size to receive i.t injections of 1 × 109 PFU Ad-TD-nsIL-12 or
PBS on day 0, 2, 4, 6, 8, and 10. Depletion mAb against Syrian hamster CD3 (clone
4F11), mAb against mouse CD4 or control Ig (mouse anti-KLH mAb) were
administered i.p with doses of 500 μg/injection every fourth day from the day
before the virotherapy to the end of the experiment and FACS analysis used to
confirm depletion. Tumor volumes were measured as in the efficacy experiments.
Statistical analysis. Statistical analysis was carried out using Graph Pad Prism 5
and SPSS 19.0 software. The results were represented as mean ± standard or





















































































































































































































Fig. 8 Ad-TD-nsIL-12 efficacy is mediated by production of inflammatory mediators. 2 × 106 HPD1NR cells were seeded into the right flank of Syrian
hamsters. When tumor volumes reached 300mm3, nine hamsters per group were each injected i.t with 100 µl PBS, 1 × 109 PFU Ad-TD-LUC or Ad-TD- IL-
12/nsIL-12 on day 0. Spleens, draining lymph nodes (DLN) and tumors were collected and analyzed by qPCR to analyze expression levels of CD83, IFN-γ,
IP10, IL-1β, IL-2, IL-6, IL-10, IL-12, and IL-21 at the indicated time points. All experiments were performed in triplicate and the mean and SEM are shown for
each group compared using an independent t-test. *p< 0.05, **p< 0.01, ***p< 0.001
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groups were analyzed using the Student’s t-test, one-way ANOVA test or
Kaplan–Meier survival analysis. Differences were considered statistically significant
when the p-value was less than 0.05.
Data availability. All data presented are available from the authors on request.
Received: 11 January 2017 Accepted: 14 September 2017
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